Danish biomarker company Nordic Bioscience announced on Friday nordicEndotrophin, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin signalling hormone-qualified in the CAP/CLIA certified Nordic Bioscience laboratory.

Alongside the company's existing product line, the assay demonstrated prognostic utility in fibrosis and cancer studies.

NordicEndotrophin joins nordicPRO-C6 and nordicPRO-C3 (in-house versions of the FDA-supported PRO-C6 and CE approved PRO-C3 assays) to deliver a one-stop solution for assessing the fibro-inflammatory axis in chronic diseases, including cardiovascular, metabolic and renal. Following PRO-C3's recent deployment on Roche IVD platforms, the new Endotrophin assay strengthens risk stratification and pharmacodynamic monitoring, Nordic Bioscience said.